{"log_id": 2440445422274807048, "direction": 0, "words_result_num": 29, "words_result": [{"probability": {"variance": 0.050246, "average": 0.811589, "min": 0.351666}, "location": {"width": 818, "top": 306, "height": 28, "left": 245}, "words": "对进行髓节骨折手术的患经过初去周的预防涂疗后再干4天的疗预静泳血栓"}, {"probability": {"variance": 0.030899, "average": 0.811466, "min": 0.417922}, "location": {"width": 797, "top": 354, "height": 27, "left": 244}, "words": "栓寨事件的发生:在一项双留试验中,学列患者髋关节骨折术使了本"}, {"probability": {"variance": 0.049317, "average": 0.761486, "min": 0.384333}, "location": {"width": 808, "top": 400, "height": 28, "left": 241}, "words": "2.一次:疗达了天治疗时,谷例患者红那次按受5"}, {"probability": {"variance": 0.038637, "average": 0.602269, "min": 0.377209}, "location": {"width": 267, "top": 451, "height": 24, "left": 244}, "words": "每安涂疗"}, {"probability": {"variance": 0.031935, "average": 0.75943, "min": 0.417348}, "location": {"width": 438, "top": 450, "height": 26, "left": 626}, "words": "安相,炎钠潍疗可使静栓检"}, {"probability": {"variance": 0.040501, "average": 0.807772, "min": 0.351407}, "location": {"width": 762, "top": 497, "height": 26, "left": 244}, "words": "事维的总体发生明减少达肝炎钠安慰红分别为3例14%)租73"}, {"probability": {"variance": 0.025157, "average": 0.911799, "min": 0.360118}, "location": {"width": 820, "top": 543, "height": 26, "left": 243}, "words": "所证录的大多数7080)件为经过静脉造影测定的无症状静脉廉栓栓塞事件。达肝癸"}, {"probability": {"variance": 0.04089, "average": 0.857021, "min": 0.366475}, "location": {"width": 822, "top": 590, "height": 25, "left": 241}, "words": "钠也可使有痛状的静脉血栓栓塞事件深静脉廉栓塞,和/或栓塞)磺达肝炎钠组和安"}, {"probability": {"variance": 0.030404, "average": 0.87427, "min": 0.422769}, "location": {"width": 823, "top": 636, "height": 26, "left": 240}, "words": "慰削组分别为1例(0.3)和19例2.7%)]的发生率量著减少,包括安慰削级中2例致命"}, {"probability": {"variance": 0.010566, "average": 0.93617, "min": 0.557966}, "location": {"width": 823, "top": 682, "height": 26, "left": 240}, "words": "性肺栓塞。使用本品2.5m常剂与安慰剂治疗后,所观察到的火出血事件皆出现手手术部位"}, {"probability": {"variance": 0.006277, "average": 0.960616, "min": 0.631855}, "location": {"width": 677, "top": 729, "height": 26, "left": 242}, "words": "且为非致命性,分别为磺达癸钠组8例(2.4%)和安慰剂组2例(0.6%)"}, {"probability": {"variance": 0.001233, "average": 0.987224, "min": 0.815965}, "location": {"width": 826, "top": 822, "height": 25, "left": 237}, "words": "对被认为是发生静脉血栓栓塞事件的高危人群并行腹部手术的患者如进行腹部癌症手术的"}, {"probability": {"variance": 0.003269, "average": 0.978792, "min": 0.668186}, "location": {"width": 824, "top": 866, "height": 28, "left": 239}, "words": "患者预防静脉血栓栓塞事件的发生:在一项双盲临床试验中,2927例患者随机接受本品"}, {"probability": {"variance": 0.031904, "average": 0.890078, "min": 0.379176}, "location": {"width": 826, "top": 913, "height": 29, "left": 236}, "words": "2.5焦剂量每日一次或达肝素5000IU每日一次治疗达71一2天,者为术前一次注射2500U"}, {"probability": {"variance": 0.000984, "average": 0.968258, "min": 0.936889}, "location": {"width": 43, "top": 960, "height": 24, "left": 237}, "words": "以及"}, {"probability": {"variance": 0.066119, "average": 0.589085, "min": 0.38596}, "location": {"width": 252, "top": 925, "height": 114, "left": 267}, "words": "料"}, {"probability": {"variance": 0.024717, "average": 0.929491, "min": 0.397562}, "location": {"width": 550, "top": 960, "height": 26, "left": 512}, "words": "外科手术部位主要为结肠肠、胃、肝以及胆囊切除或其"}, {"probability": {"variance": 0.023116, "average": 0.788378, "min": 0.605998}, "location": {"width": 104, "top": 1006, "height": 23, "left": 236}, "words": "佳胆道系"}, {"probability": {"variance": 0.009941, "average": 0.956035, "min": 0.593511}, "location": {"width": 543, "top": 1005, "height": 28, "left": 520}, "words": "行手术。进行泌尿系统(除了肾脏)或妇科手术、腹腔镜"}, {"probability": {"variance": 0.033892, "average": 0.903195, "min": 0.410579}, "location": {"width": 378, "top": 1050, "height": 31, "left": 236}, "words": "手术血管手术的患者不包括在该究中"}, {"probability": {"variance": 0.00536, "average": 0.965941, "min": 0.663168}, "location": {"width": 829, "top": 1146, "height": 34, "left": 234}, "words": "在该项研究中肝癸钠和达肝素治疗组中静脉血栓栓塞事件总体发生率分别为4.6%"}, {"probability": {"variance": 0.03687, "average": 0.879081, "min": 0.461011}, "location": {"width": 152, "top": 1194, "height": 23, "left": 265}, "words": "7/1027)6.1"}, {"probability": {"variance": 0.020035, "average": 0.911856, "min": 0.386084}, "location": {"width": 578, "top": 1194, "height": 25, "left": 483}, "words": "021险比减少为25.8%[95%C11[-49.7%,9.5%]。两治疗组"}, {"probability": {"variance": 0.011324, "average": 0.948717, "min": 0.49075}, "location": {"width": 829, "top": 1241, "height": 26, "left": 233}, "words": "之间静脉血栓栓塞事件总体发生率没有显著差异,该差异主要由于无症状性远端深静月血栓"}, {"probability": {"variance": 0.010704, "average": 0.94286, "min": 0.604574}, "location": {"width": 830, "top": 1287, "height": 30, "left": 233}, "words": "栓塞事件的减少所致。两治疗组之间症状性深静脉血栓栓继事件的发生率相似:磺达癸钠"}, {"probability": {"variance": 0.027781, "average": 0.902975, "min": 0.379945}, "location": {"width": 829, "top": 1336, "height": 30, "left": 233}, "words": "和达肝素治疗组中的发生率分别为6例(0.4例0.3%。在进行癌症手术69%的患"}, {"probability": {"variance": 0.015915, "average": 0.922346, "min": 0.568302}, "location": {"width": 778, "top": 1383, "height": 29, "left": 232}, "words": "者的大亚中,磺达肝炎钠和达肝素治疗中静脉血栓检基件的发生率分别为"}, {"probability": {"variance": 0.005934, "average": 0.878269, "min": 0.777289}, "location": {"width": 44, "top": 1433, "height": 22, "left": 230}, "words": "7.7"}, {"probability": {"variance": 0.040791, "average": 0.846714, "min": 0.364636}, "location": {"width": 642, "top": 1480, "height": 29, "left": 230}, "words": "达肝达治疗维大血事件的发生率分别为品2、4%"}], "language": 3}